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Abstract
Background: Recent studies have implicated viral characteristics in accounting for
the variation in the HIV set-point viral load (spVL) observed among individuals. These
studies have suggested that the spVL might be a heritable factor. The spVL, however,
is not in an absolute equilibrium state; it is frequently perturbed by immune
activations generated by co-infections, resulting in a significant amplification of the
HIV viral load (VL). Here, we postulated that if the HIV replication capacity were an
important determinant of the spVL, it would also determine the effect of co-infection
on the VL. Then, we hypothesized that viral factors contribute to the variation of the
effect of co-infection and introduce variation among individuals.
Methods: We developed a within-host deterministic differential equation model to
describe the dynamics of HIV and malaria infections, and evaluated the effect of
variations in the viral replicative capacity on the VL burden generated by co-
infection. These variations were then evaluated at population level by implementing
a between-host model in which the relationship between VL and the probability of
HIV transmission per sexual contact was used as the within-host and between-host
interface.
Results: Our within-host results indicated that the combination of parameters
generating low spVL were unable to produce a substantial increase in the VL in
response to co-infection. Conversely, larger spVL were associated with substantially
larger increments in the VL. In accordance, the between-host model indicated that
co-infection had a negligible impact in populations where the virus had low
replicative capacity, reflected in low spVL. Similarly, the impact of co-infection
increased as the spVL of the population increased.
Conclusion: Our results indicated that variations in the viral replicative capacity
would influence the effect of co-infection on the VL. Therefore, viral factors could
play an important role driving several virus-related processes such as the increment
of the VL induced by co-infections. These results raise the possibility that biological
differences could alter the effect of co-infection and underscore the importance of
identifying these factors for the implementation of control interventions focused on
co-infection.
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At present, the role of viral genetic factors in the HIV epidemic is poorly understood.
Many different HIV genetic subtypes circulate worldwide as well as their recombinant
forms [1]. Moreover, there is a substantial variation in the length of the asymptomatic
(chronic) phase of HIV infection, ranging from a few months to many years. This variation
has been correlated with the so-called set point viral load (spVL), defined as the measure
of the HIV concentration in blood during the chronic stage of the infection, representing
the quasi-steady state equilibrium between virus production and clearance [1,2].
The functional differences and epidemiological significance of these variations are
still unclear [3,4]. Several studies have indicated that host genetic factors can partially
explain the variation observed in the spVL [5-7]. In addition, some other studies have
revealed potential differences in the replicative capacity among different virus geno-
types [8-13]. As a result, it has been suggested that if viral factors can affect the effi-
ciency of viral replication and can be preserved from one infection to the next, this
would imply a significant role of viral genetic factors determining the spVL [14].
Recent studies conducted to assess this hypothesis have evidenced that virus charac-
teristics might indeed explain a significant proportion of the variation in the viral load
(VL) observed among individuals and suggested that the spVL might be a heritable fac-
tor [15-18]. Further studies examining the HIV replicative capacity support this asso-
ciation between the replicative capacity of the virus and the VL [19,20]. These results
have profound implications for important virus-related processes in which the VL is a
key determinant, such as the progression, and especially in the transmission of the
infection. This is given that infectiousness can be directly correlated with the concen-
tration of HIV-RNA in plasma, which associates with shedding of the virus into genital
track secretions [21,22]. The evidence suggests a strong correlation between the VL
and HIV transmission rates [23-25]. Consequently, if viral genetic factors influence the
concentration of the virus during the chronic stage of the infection, these viral charac-
teristics might indeed play an important role on the transmission of the infection.
The spVL, however, is not in an absolute equilibrium state; it is frequently perturbed
by immune activations generated by the invasion of other pathogens, resulting in a sig-
nificant amplification of the VL. Changes in the host immune response induced by
concomitant infections (co-infection) may account for transient increments in the VL
that could make the host more infectious and increase the risk of transmission of the
virus during the chronic stage of the infection [26-28]. This transient amplification of
the VL generated by co-infection may be an important contributor to the successful
transmission of the infection, especially in areas were the immune system is constantly
challenged by multiple infections, such as in sub-Saharan Africa [29-31].
Furthermore, there is substantial heterogeneity in the effect of co-infection at the
individual and population levels. Within individuals, the co-infection induced incre-
ment of the VL varies greatly [32-34]. Likewise, the effect of co-infection in the spread
of the infection at the population level depends on several behavioral and epidemiolo-
gical factors related to the stage and the distribution of the HIV epidemic within the
population. Co-infections with sexually transmitted infections (STI) such as gonorrhea
and chlamydia would have the highest impact on the transmission of the virus in
populations where the epidemic is concentrated in the high risk (core) groups [35,36].
Conversely, infections prevalent in the general population such as malaria and herpes
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infection when the epidemic has invaded the general population [36,37].
Based on the biological evidence previously discussed, we suspect that viral factors
might contribute to the variation in the effect of co-infection at host and population
levels. Here, taking a simple modeling approach, we examined how viral factors might
alter the dynamics of the virus population in the presence of co-infection and gener-
ated variation in the effects of co-infection among individuals. We expect that viruses
with high replicative capacity that sustain elevated spVL would also generate larger
transient increments in the VL in response to host immune activations induced by co-
infection. In contrast, viruses with poor capacity to infect target cells and replicate
would generate lower spVL and consequently lower VL increments in response of co-
infection. Since the transmission efficiency of the virus among individuals is associated
with the viral burden, highly infectious individuals would have viral characteristics that
maximize the increment of the VL in the presence of co-infection. This result might
have important implications at both the individual and the population levels.
To assess this hypothesis, we generated a mathematical model that describes the
dynamics of HIV and a concomitant pathogen within the host to evaluate the variation
of the viral replicative capacity on the spVL and the increment on the VL in response
to co-infection. Additionally, we evaluated the effects of these variations at the popula-
tion level.
Methods
We developed a deterministic differential equation compartmental model based on two
independent models that describe the dynamics of HIV and a parasitic infection,
namely malaria.
HIV model
The basic model of HIV dynamics implemented here has three variables: T the popula-
tion sizes of uninfected cells, T* infected cells, and V free virus particles [38-40]. These
quantities denote the total abundance of the given population per milliliter (mL) of
blood, and their dynamic is described by the following system of differential equations:
dT
dt
= s − (dt + kvV)T (1)
dT∗
dt
= kvVT − δT∗ (2)
dV
dt
= NδT∗ − cV, (3)
where s represents the production rate of activated immune (CD4+ T) cells, dt the
natural death rate of activated immune cells, kv the HIV infection rate of activated
immune cells, δ death rate of HIV infected cells, N the HIV production rate by an
infected cell, and c the HIV removal rate. The magnitudes of these parameters are
summarized in Table 1. From this system of differential equations it is possible to
determine the concentration of the virus population at equilibrium, which might be
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following equation [38]:
¯ V =
Ns
δc
−
dt
kv
. (4)
This equation shows that virus concentration at equilibrium ( ¯ V ) may depend on
virus factors that determine its replicative capacity: the infection rate of immune cells
(kv) and the production rate by infected cells (N). Since these parameters represent
intrinsic characteristics of the virus, we focused on evaluating the effect of such varia-
tions on the VL burden generated by the presence of a concomitant pathogen.
Malaria model
Malaria was selected as the concomitant infection based on substantial biological and
epidemiological evidence suggesting an important malaria-HIV interaction at the indi-
vidual level and across regions where their incidence overlap geographically. Several
studies have demonstrated the increment of VL in individuals with acute malaria
[29,32,41,42]. Moreover, the risk of HIV infection is higher in areas with high malaria
prevalence [43], and malaria has been proposed as an important facilitator for the
spread of HIV in sub-Saharan Africa [36,43].M a l a r i ai sad i s e a s ec a u s e db yp r o t o z o a
of the genus Plasmodium, which are transmitted as sporozoites through bites of
Table 1 Co-infection within-host model parameter values
Parameter Value Reference
Rate of red blood cell production (Δ) 2.5 × 10
8 cells/ml day [49,50,79]
Natural death rate of uninfected red blood cells (μx) 0.0083/day [46,49]
Infection rate of red blood cells by merozoites (km) 2.5 × 10
-10/merozoite
day
[46,49]
Differentiation rate of merozoite (μ1) 0.5/day [46,49]
Natural death rate of infected blood cells (μy) 0.025/day [46,49]
Clearance rate of infected red blood cells due to the immune
system (μc)
1×1 0
-8/cell day [50]
Natural death rate of free merozoites (μm) 48/day [46,49]
Death rate of merozoites by contact with immune cells (μh)1 × 1 0
-8/cell day [46,49]
Merozoite production per infected red blood cell (r) 16 [46,49]
Production rate of immune cells (malaria specific) (ε)1 × 1 0
-4 cell/ml day [47]
Proliferation rate of immune cells in response to infected red
blood cells (ly)
2×1 0
-8/cell day [50]
Proliferation rate of immune cells in response to merozoites (lm)3 × 1 0
-8/merozoite day [50]
Maximum number of activated immune cells per ml of blood
(Tmax)
1.5 × 10
6 cell/ml [58]
HIV infection rate for nonspecific immune cell (kv) [0.1 × 10
-5 -2×1 0
-5]
virion/day
Representative
values
Production rate of immune cells (s)1 × 1 0
4 cell/ml day [38]
Growth rate of non-specific immune cells (rT) 0.03/day [80]
Natural death rate of immune cells (dt) 0.01/day [81]
Death rate of HIV infected cells (δ) 0.7/day [58]
HIV production by an infected cell (N) [20-300] virions/cell Representative
values
HIV removal rate (c) 23/day [82]
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invade hepatocytes and replicate asexually. Each sporozoite produces thousands of
merozoites per infected hepathocyte. This stage is followed by the invasion of mature
red blood cells (erythrocytes) by merozoites. The rupture of an infected erythrocyte
releases a few dozens of merozoite progeny that are competent to infect new erythro-
cytes and thus begin a new cycle [44,45].
To introduce malaria parasites into the system, we implemented a model developed
earlier [46] and used by several authors [47-50] to study the population dynamics of X
uninfected red blood cells, Y infected red blood cells, M free merozoites, and Tm acti-
vated immune cells against malaria infection. This model focuses on the erythrocytic
cycle of the parasite with an immunological response by the host directed against mer-
ozoite and infected red blood cells. The model assumes that the net rate of red blood
cells infection is proportional to the density of uninfected red blood cells and the den-
sity population of free merozoites (kmMX). Likewise, the T immune cell proliferation is
proportional to the density of the T cell and free merozoite populations (lmMTm), and
the T cell-mediated killing of free merozoites and infected red blood cells are propor-
tional to the density of the malaria specific immune cells (μnTmM), ignoring the stimu-
lation of B cells and other type of immune cells (processes that most probably are
summarized by the density of the specific T cells). The system is described by the fol-
lowing system of differential equations:
dX
dt
=   − μxX − kmMX (5)
dY
dt
= kmMX − (μ1 + μy)Y − μcYTm (6)
dM
dt
= rμ1Y − kmMX − (μm + μhTm)M (7)
dTm
dt
= ε +

λyY + λmM

Tm − dtTm, (8)
where Δ stands for the rate of red blood cell production, μx the natural death rate of
uninfected red blood cells, km the infection rate of red blood cells by merozoites, μ1
the differentiation rate of merozoites, μy natural death rate of infected red blood cells,
μc clearance rate of infected red blood cells due to the immune system, μm natural
death rate of free merozoites, μn death rate of merozoites by contact with immune
cells, r merozoite production per infected cell, ε rate of immune cell production, ly
proliferation rate of immune cells in response to infected red blood cells, and lm pro-
liferation rate of immune cells in response to merozoites. The parameter values are
summarized in Table 1.
Within-host co-infection model
To link the within-host and between-host model, we developed a so-called nested
model that connects the dynamic processes that occur at both scales. These kind of
models have been previously used in epidemiology primarily to understand the patho-
gen evolution [51]. As previously discussed, co-infection activates host immunity,
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be a direct consequence of T helper cell (CD4+ T) activation that consequently raises
the number of target cells susceptible to virus infection [52]. The increment in the
pool of susceptible target cells has been observed in reaction to different agents that
induce an immune response such as influenza vaccine [53], tetanus immunization
[33,54], and malaria parasites [42,55]. This biological argument was used to link the
HIV and malaria models in a single co-infection model, and has also been used by
Jones and Perelson [56] to model the effect of vaccination on chronically HIV positive
persons and the effect of opportunistic infections on patients treated with antiretroviral
therapy [57]. But the within-host co-infection model developed here is the first model
to include the dynamics of more than one infection simultaneously to evaluate the
effect of a concomitant infection on the dynamics of HIV.
It is important to note, however, that the immune stimulation that promotes HIV
replication is multifactorial, and cell proliferation is only one of these mechanisms. For
example, malaria infection also stimulates HIV transcription in other ways such as the
activation of viral transcription via cytokines [55]. Therefore, the model presented here
is a simplification of the effect of co-infection on the virus population and only
describes one of the possible mechanisms in which parasites might affect the immune
pathway that could alter the replication of the virus.
For the complete model of co-infection, the HIV and malaria models previously
described were linked by depicting the mechanism in which malaria parasites stimulates
an immune response in terms of activation and proliferation of malaria activated immune
cells (Tm), which in turn become available to HIV infection. The model includes a maxi-
mum number of immune cells per mL of blood (Tmax) [58]; thus, the immune cell popula-
tion will grow in a logistic fashion. After linking the two models, the dynamic of the HIV-
malaria co-infection is described by the following system of differential equations:
dX
dt
=   − μxX − kmMX (9)
dY
dt
= kmMX − (μ1 + μy)Y − μcYTm (11)
dM
dt
= rμ1Y − kmMX − (μm + μhTm)M (12)
dTm
dt
= ε +

λyY + λmM


1 −
Tm + T + T∗
Tmax

Tm − (dt + kTmV)Tm (13)
dT
dt
= s +

1 −
Tm + T + T∗
Tmax

rTT − (dt + kvV)T (14)
dT∗
dt
= kvVT + kTmVTm − δT∗ (15)
dV
dt
= NδT∗ − cV. (16)
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tion rate (N) on the increment of the VL induced by co-infection by conducting several
numerical simulations of the model evaluated over the bi-dimensional parameter space
generated by the range parameter values of 0.1 × 10
-5 to 2 × 10
-5/day for the HIV
infection rate (kv), and 20 to 300 virions/cell for the HIV production rate (N). We first
simulated the system with HIV alone (in absence of co-infection), and then we gener-
ated several simulations with the complete system (HIV/malaria co-infection). Due to
the uncertainty associated with HIV infection rate of immune cells produced by the
presence of malaria parasites (kTm), we explored four different values for this para-
meter, which were proportional to the values used for the HIV infection rate (kv): kTm
= kv,k Tm = kv/10, kTm = kv/20, kTm = kv/30. The simulations started with the introduc-
tion of HIV alone; when the dynamics of the virus reached a steady state equilibrium
(the spVL), parasites were introduced into the system (day t = 600). We recorded the
VL immediately before the introduction of parasites, which represented the value for
the spVL, and the following 30 days after the beginning of the rise of the VL generated
by co-infection. The values recorded during these 30 days were then averaged to esti-
mate the increment on the VL generated by co-infection.
To compare spVL and the increment on the VL induced by co-infection, we sampled
the parameter space (kv,N ) across several diagonal transects which generated broad
combinations of the two parameters. These combinations were then used to calculate
the spVL and its corresponding increment on the VL induced by co-infection. This
information was then summarized in the geometric per capita growth rate of the virus
during co-infection estimated for each combination of parameters.
Effect of co-infection at the population level
Understanding how concomitant infections could influence between-host transmission
and epidemic dynamics represents a major challenge in epidemiology. The scenario is
even more complicated when possible viral genetic differences might introduce hetero-
geneity into the outcome of co-infection. For that reason, using the within-host model
described previously, we attempted to evaluate the effect of virus heterogeneity on
transient co-infection-induced amplification of the VL at population level.
To estimate the effect of co-infection on the spread of HIV at population level, we
implemented a standard deterministic population model constructed by Abu-Raddad
and coworkers [36,59]. The model is a deterministic compartmental model that strati-
fies the population into compartments according to HIV sero-status and stage of HIV
infection, and sexual-risk activity group. The model included the three stages of HIV
infection, acute, chronic and late, each one with its corresponding probability of trans-
mission per sexual contact estimated from the literature (in the Additional file 1: Table
S1). Details of the model are described elsewhere [36,59], and a short description of
the model is included in the Additional file 1.
For this model, the functional relationship between VL and the probability of trans-
mission per sexual contact was used as the within-host and between-host interface. The
model assumes that the effect of the VL on the infectiousness follows the empirical rela-
tionship between VL and transmission probability per sexual contact as observed initi-
ally by Quinn and colleagues [23]: pHIV
I(i)→S(j) =2 . 4 5 log(vlH/vlB)pHIV ,w h e r epHIV
I(i)→S(j) stands
for the probability of transmission per sexual contact for an infected individual from the
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HIV is the baseline
probability of transmission per sexual contact in the chronic stage of the infection, vlH
is the amplified VL, and vlB is the baseline VL. The baseline probability of transmission
per sexual contact in chronic stage was assumed to be p
HIV = 0.0008, with a VL of vlB =
15 000 virions/mL [23]. Thus, as an example of the calculations performed, at vlH =3 3
478 virions/mL, the probability of transmission per sexual contact in the chronic stage is
pHIV
I(i)→S(j) =2 . 4 5 log(33478/15000) × 0.0008 = 0.00109. Finally, to account for the potential
effect of the VL on the HIV disease progression to AIDS, each log10 rise in the VL
increases the rate of HIV progression to the latest stage of the infection by twofold [28].
The spVL and its corresponding co-infection induced increment on the VL pre-
viously evaluated for each combination of parameters were used to compare the spread
of HIV in two different populations: one population free of co-infection, in which the
probability of transmission per sexual contact during the chronic stage of the HIV
infection was estimated at the spVL, and the corresponding population affected by co-
infection, in which the probability of transmission during the chronic stage of the HIV
infection was estimated by including the increment on the VL induced by the conco-
mitant infection with malaria. To calculate the probability of transmission in the popu-
lation affected by co-infection, it was assumed that each individual has, on average,
one episode of malaria infection per year. Thus, the mean VL per year was the average
of the spVL during 11 months and the increased VL for the month of the co-infection.
The model was also evaluated assuming two and four episodes per year.
The system was evaluated at the endemic equilibrium (see the Additional file 1 for
details). After the equilibrium solution was found through convergent successive
approximations, the total incidence was calculated. Finally, to evaluate the effect of co-
infection under different viral replicative capacities, the direct effect of co-infection on
the HIV incidence was measured by using population attributable fractions (PAF),
which is defined as the proportional reduction in disease risk over a specific time inter-
val that can be achieved by eliminating HIV/malaria co-infection from the population
[60,61]. It is calculated as:
PAF =

1 −
IRvlsp
IRHvl

× 100%, (17)
where IRvlsp is the incidence rate of HIV with the spVL, and IRHvl is the HIV incidence
rate with the heightened VL in presence of co-infection for each combination of para-
meters kv and N as defined previously [36]. Due to the absence of consistent data report-
ing the effect of malaria-related morbidity on sexual behavior [62], we assumed that the
episodes of malaria were asymptomatic as a consequence of the partial immunity gener-
ated by the consistent exposure to the parasite in areas where malaria is endemic [63,64].
Results
Within-host model
The graph for the spVL (in absence of co-infection), generated in the parameter space
implemented, indicated that the values for the spVL were mainly dependent on the virus
replicative capacity (N) (Figure 1A). In contrast, the infection rate of immune cells (kv)
had a small effect on the estimated spVL. This result might be related to the limited num-
ber of immune cells available to be infected by the virus. Therefore, regardless of the
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cells present in the system. For that reason, the number of virions produced by an infected
cell (N) is the main parameter that governed the estimated spVL.
On the other hand, the results from the complete system (HIV/malaria co-infection)
indicated that both parameters, the infection rate of immune cells (kv) and the produc-
tion rate by infected cells (N), determine the amplification of the VL in presence of co-
infection. In general, the within host co-infection model indicated that small values for
the two parameters evaluated, the HIV production rate by infected cell (N)a n dt h e
HIV infection rate (kv), produced small increments on the VL when dual infection
with HIV and malaria is present. Conversely, the increment on the VL increased as
both parameters increased. Different values for kTm (HIV infection rate of immune
cells for co-infection), however, generated different patterns. When kTm = kv, the differ-
ences on the increment of the VL in response to co-infection were determined by the
variation on the HIV production rate per infected cell (N) (Figure 1B). The highest VL
amplification was produced at a very low HIV infection rate (kv =0 . 1×1 0
-5) and high
HIV production rate per infected cell (N = 300). Contrary to expectation, when kv
increases, the increment in the VL generated by co-infection decreases. This behavior
is derived from the ability of the virus to infect new target cells activated by malaria
Figure 1 Increment on VL induced by co-infection as a result of HIV replicative capacity. The effect
of HIV infection rate (kv) and production rate (N) on the increment of the VL generated by co-infection
was evaluated using the bidimensional parameter space with range 0.1 × 10
-5 to 2 × 10
-5/day for kv, and
20 to 300 virions/cell for N. In A spVL in absence of co-infection; B kTm = kv;CkTm = kv/10; D kTm = kv/20;
and E kTm = kv/30; where kTm indicates the HIV infection rate for malaria immune cells.
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eration of these immune cells (Figure 2A). Consequently, this overexploitation of the
new target cells by the virus at early stages of co-infection prevented an effective
immune response to control malaria. This scenario seems to be unrealistic since indivi-
duals infected with HIV are able to have an effective immune cell proliferation in the
presence of concomitant infections [65,66]. In addition, the increment on the VL in
individuals dually infected with HIV and another pathogen is associated with an incre-
ment on the CD4+ T cells [41,42].
On the other hand, when the kTm was a fraction of the kv, the increment of both
parameters, the HIV production rate per infected cell and the HIV infection rate,
induced larger increments in the VL in response to co-infection. This result suggests
that a large kTm might affect the availability of the new target cells for infection by
the virus by diminishing the potential cell proliferation (Figure 2). When kTm = kv/
10, the effect of the overexploitation of target cells by the virus is still evident at
high HIV infection rate (starting from kv =1×1 0
5) (Figure 1C). This effect is
diluted when kTm = kv/20 (Figure 1D), and the target cell concentration stabilizes
with no substantial changes at smaller fractions of kv (Figure 1E). For that reason,
and to include possible differences on the HIV infection rate generated by the avail-
ability of new target cells for HIV infection, the remaining results were derived
assuming kTm = kv/20.
Figure 2 Time course of the CD4 cells in presence of co-infection with different HIV infection rates
of malaria immune cells kTm. Figures illustrate the CD4 cell dynamics from day 550 to day 900 keeping
N and kv constant: kv = 1.2 × 10
-5 and N = 200. For A, kTm = kv, the virus rapidly infects the new target
cells impeding the proliferation of the CD4 cells. In B, kTm = kv/10, the effect of the overexploitation of
target cells by the virus is still evident. In C and D this effect is diminished, with kTm = kv/20 and kTm = kv/
30 respectively.
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parameters used. The combination of parameters generating low spVL were almost
unable to produce an increment on the VL when parasites were introduced into the
system (Figure 3A, B, and 3C). Conversely, larger spVL associated with more efficient
viral replicative capacity generated much larger increments in the VL in response to
co-infection (Figure 3D, E, and 3F). After the introduction of parasites, there was a
transient increment on virus concentration followed by a peak and successive decay to
the original spVL. It is possible to observe a time delay between the introduction of
the parasite and the peak of the VL (approximately 45-50 days). It might represent the
time it takes for the parasite to increment its population to generate an immunological
response required to perturb the VL. These viral dynamics in response to immune
Figure 3 Time course of the VL in presence of co-infection with different set of parameters kv and
N. Figures illustrate the HIV dynamics from day 550 to day 800 for selected set of parameters from Figure
1C. In A, kv = 0.2 × 10
-5 and N = 50; B, kv = 0.5 × 10
-5 and N = 120; C, kv = 0.6 × 10
-5 and N = 170; D, kv =
0.9 × 10
-5 and N = 190, E, kv = 1.2 × 10
-5 and N = 200; F, kv = 1.8 × 10
-5 and N = 280
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mathematical models [56,57].
On average, the VL returned to baseline levels six to eight weeks after the immune
stimulation, consistent with other studies in which a large increase in the VL was
observed during acute malaria and after influenza vaccine [32,53]. The average incre-
ment in the VL generated by co-infection, estimated from the 30 days recorded during
the co-infection episode, ranged from 500 to 800 000 virions/mL. This variation is con-
sistent with the ranges estimated from studies designed to evaluate the effect of
malaria on the VL of HIV-positive individuals in Africa [32,42].
The positive correlation between the spVL and the increment on the VL induced by
co-infection is illustrated in Figure 4A, which was generated with the parameter values
Figure 4 Correlation between the spVL and the increment on the VL in response to co-infection.
We used different combination of the parameters kv and N, in which both parameters increase. The values
used are reported in Table S1 in the Additional file 1. In A, the results suggest that viruses with low
replicative capacity conducing to low spVL are generating limited increments on the VL. Conversely, viruses
with potent replicative capacity that are able to produce elevated spVL would generate much larger
increments on the VL. The pattern follows a logistic fit, which suggests a saturation effect at very high
spVL. In B, the geometric per capita rate of growth was estimated for each spVL, and the pattern also
shows a saturation fashion.
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poor infection rate of immune cells (kv) and the production rate by infected cells (N),
were not able to respond to increments in the activated target cells induced by the pre-
sence of concomitant infections. Consequently, the co-infection related increment in the
VL generated by these viruses was fairly small. At lower spVL, the relationship between
the increment on the virus concentration and the spVL is exponential, suggesting that
viral genotypes with potent replicative capacity, and thus elevated spVL, were associated
with large co-infection induced increments in the VL. The pattern followed a logistic
function, suggesting a saturation effect at very high spVL (Figure 4A). Additionally, the
high HIV per capita growth rate during co-infection observed at large spVL might reflect
the high replication capacity of these viruses that were able to effectively respond to
increments in the target cell population (Figure 4B).
Between-host model
The functional relationship between the viral load and the probability of transmission
per sexual contact was used to link the viral replicative capacity and the effect of co-
infection at the population level. As expected, and in accordance with the immunologi-
cal model, the PAF analysis indicated that co-infection would have a negligible impact
in populations where the circulating virus has low replicative capacity, reflected in low
spVL. In contrast, the impact of co-infection would increase as the spVL of the popu-
lation increased, and this effect levels off at around spVL 1 × 10
5 (Figure 5). This result
indicates that viruses with high replicative capacity that are able to maintain elevated
Figure 5 Correlation between the spVL and the PAF. Using combinations of the parameters kv and N
(see Table S2 in the Additional file 1), the between-host model indicated that co-infection would have a
negligible impact in populations where the circulating virus has low replicative capacity reflected in low
spVL. Conversely, the impact of co-infection would increase as the spVL of the population increases, until
the effect tends to stabilize at spVL around 1 × 10
5. Black solid line indicates the PAF estimated from one
episode of malaria; blue dashed line, two episodes; red dashed-dotted line, four episodes.
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HIV infections directly caused by co-infection. This result was consistent regardless of
the average number of co-infection episodes per year. In addition, the number of co-
infection episodes has almost no impact on the PAF at low spVL; even four episodes
were not able to produce a PAF larger than 1% when the spVL is lower than 2 × 10
4 .
Discussion
In this work, we explored factors that could introduce variation in the effect of co-
infection on HIV dynamics at individual and population levels. We postulated that if
the HIV replication capacity was an important determinant of the spVL, it would also
determine the effect of co-infection on the dynamics of the virus. Here, using a pre-
viously described mathematical model to represent the single dynamics of HIV at host
level [38,39], it was determined that the variation in the viral replication capacity,
described primarily by the HIV production by infected cell (N), generated different
viral load set-points. Moreover, the influence of the virus replicative capacity on the
increment in VL generated by co-infection was evaluated using a within-host mathe-
matical model of HIV/malaria co-infection which examined the effect of variation in
viral infection rate of immune cells (kv) and the production rate by infected cells (N).
The model indicated that the viral replication capacity regulated by these parameters
would strongly influence the induced increment of the VL when a concomitant infec-
tion is introduced in the system. In contrast to the spVL, in which the infection rate
plays a minor role and is primarily determined by the production rate per infected cell,
the new available target cells generated by the presence of a concomitant pathogen is a
suitable condition for virus genotypes with higher infection rate of immune cells.
In addition, our model suggested the existence of a differential HIV infectivity rate
for the new target cells generated by co-infection. Infection agents such as Plasmodium
induce localized immune response occurring in specific organs such as the spleen [66],
which produce a decrease in peripheral T cells as consequence of a sequestration of
these cells to specific lymphoid organs [65]. These characteristics might generate a
compartmentalization of the system in which not all new target cells would be avail-
able to the virus. Consequently, the HIV infection rate for the new target cells gener-
ated by co-infection (kTm in our model) might be a fraction of the HIV infection rate
for non-specific immune cells (kv), as suggested by the model.
Low virus replicative capacity generated modest increments on the VL in response to
co-infection. Regardless of the co-infection induced proliferation of target cells, the low
replicative capacity prevented an effective viral response to the newly available acti-
vated target cells. Conversely, viruses with more efficient capacity to infect target cells
and replicate were able to produce much stronger increments on the VL when a larger
population of target cells was available. Despite the introduction of new target cells to
the system, the effect of co-infection could primarily depend on the ability of the virus
to efficiently exploit the temporal rise of the target cell population. This, in conse-
quence, would generate a considerable increment on the VL when the immune system
of the host is stimulated by the presence of a concomitant pathogen. This result sug-
gests that viral factors could play an important role not only in determining the spVL
but also in driving several virus-related p r o c e s s e ss u c ha st h ei n c r e m e n to ft h eV L
induced by co-infections.
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tious individuals. HIV-positive persons that sustain high spVL might therefore be able
to produce large increments of virus concentration in response to immune stimula-
tions and consequently become much more infectious individuals, compared to those
maintaining low spVL, even in the presence of the same concomitant pathogen. This
argument was then evaluated at the population level by linking the results from the
within-host model with a population model using the functional relationship between
viral load and probability of HIV transmission per sexual contact. We generated several
virtual populations with different viral replicative capacities that sustained different
mean spVL in which the direct effect of co-infection on the incidence of HIV was then
evaluated. The results from these simulations were consistent with the results from the
host level model and raise the possibility that co-infection might play a substantial role
in the spread of HIV in populations where the circulating viruses maintain elevated
spVL. Conversely, co-infection would not be an important driver of the epidemic in
populations with low spVL.
This study is a theoretical exercise aimed to explore further implications of the varia-
tion of viral genetic factors on the natural history of HIV. To achieve this goal, we
developed a within-host co-infection model based on two well-known and extensively
used mathematical models describing the within-host dynamics of HIV and malaria
infections. These two models were linked by the immune response induced by the con-
comitant infection with Plasmodium that increased the target cell population for HIV
infection. This mechanism, however, is only one of the several mechanisms in which
the invasion of another pathogen stimulates the replication of HIV [41,53,67,68]. The
interaction between HIV and concomitant pathogens appears to be multi-factorial at
cellular and immunological levels [67]. For example, the transcriptional signaling used
by lymphocyte cells to regulate cell functioning is also used by HIV to regulate virus
production. During co-infection, cytokines (small proteins secreted by specific cells of
the immune system used for local signals between cells during response to infection
[69]) might enhance their susceptibility to HIV infection and stimulate production of
viruses for weeks to months without significant cytopathic effects [70,71].
Moreover, other infections might have additional mechanisms in which they could
affect the transmission of HIV. For example, the genital reactivations of HSV-2 gener-
ate local immune activations in genital ulcerations that might increment HIV shedding
in the genital tracks [72]. This STI infection not only affects the risk of transmission
but also increases the risk of acquisition in HIV-negative individuals, a characteristic
that considerably affects the mode in which HSV-2 influences the pattern of HIV
transmission at the population level [36,59]. The differences in which other infections,
besides malaria, interact with HIV are not considered in this study, as they may affect
the results observed at the population level.
We emphasize that this work relies entirely on a hypothetical relationship between
viral genotypic factors and the VL. As noted previously, regardless of the evidence
about the relationship between viral genetic factors and the VL [15-17], the role of
virus genotype on the natural history of HIV infection is controversial [73,74], and the
evidence about differences in VL among populations is limited and very speculative
[3,75]. Therefore, our study indicates the importance of conducting such studies that
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studies would help us better understand the extensive variation on the HIV epidemic.
Furthermore, our model does not include an evolutionary response of HIV. The virus
might evolve at the two scales studied; at between-host level, the virus evolves rapidly
to evade the host immune system [76]. This selection pressure favors the increment of
the virus replicative capacity in the course of the infection [19]. On the other hand, at
between-host level some theoretical studies have suggested that the trade-off generated
between the transmission and progression of the infection implies and evolutionary
stable strategy that favors virus strains with intermediate virulence [77,78]. These selec-
tion forces acting on both scales might have some important implications on the trans-
mission efficiency of the virus that might alter the results discussed in this study.
Future work would include the potential impact of these forces acting on the virus
replicative capacity and the interactions with a concomitant pathogen.
Regardless of the limitations previously discussed, the model presented here high-
lights the possibility that viral factors might have an important impact on the role of
co-infection on the spread of HIV. Therefore, understanding their variations would be
a key element in the design of control interventions to prevent HIV transmission. To
pursue this goal, however, it would be necessary to evaluate the results from the theo-
retical model proposed here with experimental data. These kinds of studies should be
conducted in HIV-positive individuals in the chronic stage of the infection with similar
CD4+ T cell count, and whose spVL have being well established. Their immune sys-
tems could be challenged with the application of previously used antigen immune sti-
mulants such as tetanus toxoid vaccine [33] or influenza vaccine [34,52]. The VL
should then be measured frequently (preferably daily) over a considerable period of
time (at least one month), to accurately delineate the dynamics of the virus during co-
infection.
As suggested by the model, biological differences could alter the effect of co-infec-
tion and underscore the importance of identifying these factors for the implementation
of effective control interventions focused on co-infection. The effect of co-infection
might not be the same among individuals and populations, and control strategies will
not necessarily have the same impact in each population. Understanding the role of
viral genetic factors on co-infection becomes an important element for developing
accurate and effective recommendations for population-level control strategies.
Additional material
Additional file 1: Table S1. A single PDF file. 9 pages that include supplementary methods. The supplementary
tables are embedded in the file [36,59,83-90].
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